Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Neurology›Condition·Updated Apr 17, 2026·v1

Parkinson Disease

Parkinson disease is a progressive neurodegenerative synucleinopathy defined by motor (bradykinesia, tremor, rigidity) and non-motor symptoms. Diagnosis is clinical but increasingly supported by biomarkers like αSyn-SAA and DaTscan. Management centers on levodopa optimization, exercise, and advanced therapies like DBS.

High Evidence194 references·760 words·4 min read·v1
NeurologyMovement DisordersNeurodegenerationParkinsonism

Quick Reference

RxDrug of choiceCarbidopa-Levodopa (25/100 mg)
AltAlternativesMAO-B inhibitors (Rasagiline), Dopamine agonists (Pramipexole), COMT inhibitors (Entacapone)
⊘AvoidTypical antipsychotics (Haloperidol), Metoclopramide, Prochlorperazine
DxTest of choiceClinical diagnosis (supported by αSyn-SAA or DaTscan)
ScKey scoreMDS-UPDRS (Motor), Hoehn & Yahr (Staging)
→When to referAtypical features (red flags), refractory motor fluctuations, or consideration for DBS
PD is a clinical diagnosis based on bradykinesia and levodopa responsiveness; management must be multidisciplinary, addressing both motor and non-motor complications early.
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded α-synuclein aggregates known as Lewy bodies. It is the fastest-growing cause of neurological disability globally, with a clinical presentation traditionally defined by the motor triad of bradykinesia, resting tremor, and rigidity. However, the modern understanding of PD has shifted toward a biological framework (SynNeurGe) that recognizes a prolonged prodromal phase involving non-motor symptoms like hyposmia and REM sleep behavior disorder.

Overview and Recommendations

Background

  • •Recognize Parkinson disease (PD) as a multisystem alpha-synucleinopathy characterized by the progressive loss of dopaminergic neurons, leading to both classic motor deficits and a wide array of non-motor symptoms (NMS).
  • •Identify the clinical phases of the disease, starting with a prodromal phase (hyposmia, constipation, REM sleep behavior disorder) that can precede motor onset by decades, followed by early-stage responsiveness to therapy and late-stage motor complications like (FOG).
  • •Understand the shifting diagnostic paradigm toward the SynNeurGe framework, which classifies the disease based on α-synuclein (S), neurodegeneration (N), and genetics (G) rather than purely clinical phenomenology.
  • •Note the demographic trends where PD disproportionately affects males (2:1 ratio) and is increasingly prevalent in aging populations, though early-onset Parkinson disease (EOPD) affects those aged 21–50 and often carries a higher genetic burden.
  • •Distinguish idiopathic PD from 'Parkinson-plus' syndromes such as (MSA) and (PSP), which typically present with more rapid progression and poor levodopa response.

Evaluation

  • •Suspect PD in any patient presenting with asymmetric motor signs, particularly a 4–6 Hz 'pill-rolling' rest tremor, lead-pipe or cogwheel rigidity, or unexplained slowness in activities of daily living.
  • •Confirm the presence of bradykinesia, the essential motor sign, by observing a decrement in amplitude or speed during repetitive movements such as finger tapping or rapid alternating hand movements.
  • •Perform a Levodopa Challenge by administering a suprathreshold dose (typically 200 mg of levodopa) and measuring the MDS-UPDRS Part III score; a >30% improvement in motor function strongly supports an idiopathic PD diagnosis.
  • •Identify 'red flags' that suggest alternative diagnoses, including early severe autonomic failure (orthostatic hypotension), vertical supranuclear gaze palsy, or falls occurring within the first three years of symptom onset.
  • •Screen for non-motor features during the clinical encounter, specifically asking about hyposmia (loss of smell), REM sleep behavior disorder (acting out dreams), and chronic constipation.
  • •Order a structural MRI to rule out secondary causes such as normal pressure hydrocephalus or vascular , though conventional imaging is often normal in early idiopathic PD.
  • •Utilize DaTscan ([123I]FP-CIT SPECT) in cases of clinical uncertainty to visualize striatal dopamine transporter density and confirm a presynaptic dopaminergic deficit.
  • •Consider a skin biopsy to detect S129 phospho-α-synuclein (pαSyn) at the C7 and Th12 dermatomes, which can highly accurately differentiate synucleinopathies from tauopathies like PSP.
  • •Assess gait and balance using dual-task challenges (e.g., walking while performing mental arithmetic) to reveal impaired motor automaticity and the risk of .
  • •Monitor orthostatic blood pressure trajectories longitudinally, as early autonomic failure is a marker for faster disease progression and increased vascular risk.
  • •Evaluate for impulse control disorders (ICD) such as pathological gambling or hypersexuality, particularly in patients already receiving dopamine agonist therapy.

Management

  • •Administer Carbidopa-Levodopa (e.g., 25/100 mg TID) as the gold standard for motor symptom control, ensuring strict adherence to dosing schedules to avoid 'off' periods.
  • •Prioritize medication timing in hospitalized patients; delays or omissions of dopaminergic doses are associated with increased morbidity and mortality in the inpatient setting.
  • •Manage 'wearing-off' fluctuations by adding adjunctive therapies such as COMT inhibitors, MAO-B inhibitors, or Amantadine-IR 200 mg/day to reduce peak-dose dyskinesia.
  • •Prescribe a cycling exercise protocol (40-60 minutes, 3 times per week) to improve movement vigor and significantly reduce the progression of urinary frequency.
  • •Implement High-Intensity Expiratory Muscle Strength Training (EMST) at 60% of maximal expiratory pressure to improve swallowing safety and prevent .
  • •Refer for bilateral subthalamic nucleus (STN) (DBS) in patients with advanced PD who experience medication-refractory motor fluctuations but remain levodopa-responsive.
  • •Utilize non-invasive neuromodulation such as transcutaneous auricular vagus nerve stimulation (taVNS) to improve gait parameters and sleep quality.
  • •Treat mild-to-moderate depressive symptoms with High-Definition Transcranial Direct Current Stimulation (HD-tDCS) targeting the left dorsolateral prefrontal cortex.
  • •Address postural deformities like camptocormia using wearable sensor-based braces that provide vibratory feedback when forward flexion exceeds a pre-set threshold.
  • •Manage chronic constipation using the '6S' model, emphasizing high fiber intake and standardized laxative protocols.
  • •Screen for and manage bone health by performing a baseline DXA scan at diagnosis and initiating Vitamin D and Calcium supplementation to prevent fragility fractures.
  • •Avoid typical antipsychotics (e.g., Haloperidol) and certain antiemetics (e.g., Metoclopramide) as they can severely exacerbate parkinsonian motor symptoms.
  • •Consider Donor (dFMT) in drug-naïve patients to improve both motor and gastrointestinal symptoms via the gut-brain axis.
  • •Transition to Continuous Subcutaneous Apomorphine Infusion (CSAI) in advanced stages if the oral route is compromised by severe or terminal illness.
  • •Provide genetic counseling for patients with GBA1 or LRRK2 variants, focusing on variable penetrance and the implications for family members.

Board Review — High Yield

  • •Lewy Bodies — Pathognomonic intracellular aggregates of misfolded alpha-synuclein.
  • •Bradykinesia — The essential clinical feature required for diagnosis; characterized by slowness and decrement in amplitude.
  • •RBD (REM Sleep Behavior Disorder) — A highly specific prodromal marker for future synucleinopathy development.
  • •GBA1 Mutation — The most common genetic risk factor for Parkinson disease.
  • •Micrographia — A classic clinical sign where handwriting becomes progressively smaller and cramped.
  • •Pill-rolling tremor — A 4–6 Hz resting tremor that typically disappears with purposeful movement.
  • •Honeymoon Period — The initial years of treatment where patients have a robust and stable response to levodopa.
  • •Freezing of Gait — An episodic 'glued to the floor' sensation, often triggered by doorways or turning.

Deep Dive — Evidence Details

References

  1. [1]

    Gregson CL, Armstrong DJ, Avgerinou C et al.. “The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.” Archives of osteoporosis (2025). PMID: 40921943 ↗

    L1cGUIDELINECited in: Definition, Synonyms, and Classification
  2. [2]

    Xavier D, Felizardo V, Ferreira B et al.. “Voice analysis in Parkinson's disease - a systematic literature review.” Artificial intelligence in medicine (2025). PMID: 40132400 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  3. [3]

    Bradley M, O'Loughlin S, Donlon E et al.. “Determining Falls Risk in People with Parkinson's Disease Using Wearable Sensors: A Systematic Review.” Sensors (Basel, Switzerland) (2025). PMID: 40648326 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  4. [4]

    Moss Lopes PR, Westphal Filho FL, Mendes Filho FSM et al.. “Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.” Movement disorders clinical practice (2025). PMID: 40406920 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  5. [5]

    Pecoraro PM, Marsili L, Espay AJ et al.. “Computer Vision Technologies in Movement Disorders: A Systematic Review.” Movement disorders clinical practice (2025). PMID: 40326633 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  6. [6]

    Sharma P, Singh SM, Mehta S et al.. “High-definition transcranial direct current stimulation for depressive and other non-motor symptoms in Parkinson's disease: a randomised, sham-controlled, cross-over study.” East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2026). PMID: 41916935 ↗

    L1bRCTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup, Differential Diagnosis, Management
  7. [7]

    Cole-Hunter T, Antic S, Lim YH et al.. “Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41772748 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  8. [8]

    Davydow DS, Okun MS, Pontone GM. “Potential Risk Factors for Psychosis in Parkinson's Disease: A Review of Cohort and Case-Control Studies.” Journal of geriatric psychiatry and neurology (2025). PMID: 39925085 ↗

    L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification
  9. [9]

    Gilat M, Nonnekes J, Factor SA et al.. “An updated definition of freezing of gait.” Nature reviews. Neurology (2026). PMID: 41513745 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Guidelines and Resources
  10. [10]

    Rigon L, Poplawska-Domaszewicz K, Metta V et al.. “The challenges with the identification of Parkinson's disease subtypes.” Expert review of neurotherapeutics (2026). PMID: 41474600 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  11. [11]

    Bougea A. “Staging and markers in Parkinson's disease and Lewy body disorders: narrative review.” Therapeutic advances in chronic disease (2025). PMID: 41146744 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  12. [12]

    Ma H, Zhu Y, Zhao X et al.. “Pyroptosis: inflammatory cell death mechanism and its pathological roles in neurological diseases and injuries.” Apoptosis : an international journal on programmed cell death (2025). PMID: 40813542 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  13. [13]

    Factor SA, Weinshenker D, McKay JL. “A possible pathway to freezing of gait in Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973500 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  14. [14]

    Höglinger GU, Lang AE. “SynNeurGe: The road ahead for a biological definition of Parkinson's disease.” Journal of Parkinson's disease (2025). PMID: 39973492 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  15. [15]

    Bendetowicz D, Planche V, Bezard E et al.. “Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease.” Journal of Parkinson's disease (2025). PMID: 39973487 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  16. [16]

    Tinazzi M, Geroin C, Siciliano M et al.. “Pain and fatigue in Parkinson's disease: advances in diagnosis and management.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 39937423 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  17. [17]

    Soto C, Mollenhauer B, Hansson O et al.. “Toward a biological definition of neuronal and glial synucleinopathies.” Nature medicine (2025). PMID: 39885358 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  18. [18]

    Lesley R, Simpson J, Dale M et al.. “Predictors of Informal Caregiver Burden in Parkinson's Disease: A Systematic Review.” Western journal of nursing research (2025). PMID: 40138495 ↗

    L2aSR_OBSCited in: Definition, Synonyms, and Classification
  19. [19]

    Cataldo E, de Oliveira Aguiar AG, Silva LAS. “A Methodological Review of Voice Acoustic Parameters, with Emphasis on Vocal Tremor: Definitions, Computation, and Software Tools.” Journal of voice : official journal of the Voice Foundation (2026). PMID: 41951462 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  20. [20]

    Fan SP, Okuzumi A, Chen PS et al.. “Parkinson's disease in transition: Genetics, biomarkers, and emerging therapeutics.” Journal of the Formosan Medical Association = Taiwan yi zhi (2025). PMID: 41353001 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  21. [21]

    Calzetti S, Calzetti G. “The nosology of tardive parkinsonism.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 41130187 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  22. [22]

    Subramanian I, Ricciardi L, Schrag A et al.. “A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.” Movement disorders clinical practice (2026). PMID: 41084417 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  23. [23]

    Brenlla C, Lazaro-Hernandez C, Fernandez M et al.. “Biomarkers of neurodegenerative parkinsonisms: From current clinical to future biological definitions - literature review and our experience.” Neurologia i neurochirurgia polska (2025). PMID: 40207871 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  24. [24]

    Markiewicz M, Madetko-Alster N, Alster P. “Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.” Frontiers in neurology (2024). PMID: 39634776 ↗

    L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification
  25. [25]

    Stinson SE, Shadrin AA, Rahman Z et al.. “Distinct metabolic signatures of Alzheimer's and Parkinson's disease revealed through genetic overlap.” EBioMedicine (2026). PMID: 41966729 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  26. [26]

    Ekert JO, Patel V, Zhou X et al.. “Enhancing 7T MRI for deep brain stimulation with deep-learning based image reconstruction and dynamic parallel transmission.” NeuroImage. Clinical (2026). PMID: 41962172 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  27. [27]

    Dinter E, Margraff JL, Schniewind I et al.. “CSF alpha-Synuclein Seed Amplification Assay results in routine clinically collected samples.” Journal of Parkinson's disease (2026). PMID: 41944207 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  28. [28]

    Elder NM, Lash EM, Tomkins-Tinch C. “An Underrecognized Problem: Missed and Delayed Carbidopa-Levodopa Administration in Emergency Department Patients With Parkinson's Disease.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41910596 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Management, Special Populations
  29. [29]

    Barbosa RP, Bastos P, Béreau M et al.. “Is being asymmetric a bad thing? Insights from a longitudinal observational study on STN-DBS Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41887013 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  30. [30]

    Park D, Lee WR, Bang M et al.. “Impact of Postoperative Chronic Back Pain Syndrome on the Incidence of Psychiatric and Brain Disorders, and All-Cause Mortality.” Journal of pain research (2026). PMID: 41710284 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  31. [31]

    Liu R, Zhang S, Xiao Y et al.. “The Effects of Digital Health Interventions on Motor Symptoms, Nonmotor Symptoms, and Quality of Life in Patients With Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Journal of medical Internet research (2026). PMID: 41818739 ↗

    L1aSR_MA_RCTCited in: Epidemiology and Risk Factors
  32. [32]

    Hemeda S, Elmadani M, Merzah M et al.. “Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41578833 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  33. [33]

    Yang D, Nepal G, Ojha R et al.. “Association between dairy consumption and Parkinson's disease: A systematic review and meta-analysis.” Public health (2026). PMID: 41544344 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  34. [34]

    Bang CS, Hasanuzzaman M, Lee JJ et al.. “Association between Helicobacter pylori infection and Parkinson's disease: A systematic review and meta-analysis.” European journal of clinical investigation (2026). PMID: 41527373 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  35. [35]

    Barer Y, Ast T, Chodick G et al.. “Incretin-based therapy and Parkinson's disease risk among patients with type 2 diabetes: Retrospective cohort study and meta-analysis.” Parkinsonism & related disorders (2026). PMID: 41468681 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  36. [36]

    Chen X, Barclay NL, Pineda-Moncusí M et al.. “Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom.” European journal of public health (2026). PMID: 41954920 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors, Differential Diagnosis, Special Populations
  37. [37]

    Bae Y, Song C, Kim S et al.. “Risk of somatoform and sleep-related disorders in Parkinson's disease: A nationwide matched cohort study.” Sleep medicine (2026). PMID: 41812492 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  38. [38]

    Kamo H, Remz M, Mehta TR et al.. “Five-year risk of cardiovascular events and falling in Parkinson's disease with orthostatic hypotension: A nationwide cohort study.” Parkinsonism & related disorders (2026). PMID: 41637898 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  39. [39]

    Davoodi L, Frouzanian M, Soleymani E et al.. “Investigating the prevalence of Toxoplasma gondii infection in Parkinson's disease patients and its association with disease severity: a case-control study.” BMC infectious diseases (2026). PMID: 41526839 ↗

    L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations
  40. [40]

    Kang MS, Jung YT, Kim S et al.. “Upper-thoracic predominance and non-vertebral fracture burden in Parkinson's disease: A matched Case-Control study.” Parkinsonism & related disorders (2026). PMID: 41468680 ↗

    L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Special Populations
  41. [41]

    Huang X, Cheng Q, Xie Y et al.. “Chinese patent medicine in the treatment of Parkinson's disease: A systematic review and network meta-analysis.” Complementary therapies in clinical practice (2026). PMID: 41505870 ↗

    L2aSR_OBSCited in: Epidemiology and Risk Factors
  42. [42]

    Cheng B, Cheng S, Wei W et al.. “Residential green space, natural environment, domestic garden, and the risk of Parkinson's disease: A prospective cohort study.” Neurobiology of disease (2026). PMID: 41759830 ↗

    L2bCOHORTCited in: Epidemiology and Risk Factors
  43. [43]

    Gusmão NA, Mateus APM, Oliveira VB et al.. “Parkinson's disease and Porphyromonas gingivalis levels: a case-control study.” Journal of applied oral science : revista FOB (2026). PMID: 41880470 ↗

    L3bCASE_CONTROLCited in: Epidemiology and Risk Factors
  44. [44]

    Gomes de Luna JR, Lima DP, Gomes VC et al.. “Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.” Frontiers in endocrinology (2026). PMID: 41924518 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup
  45. [45]

    Zhou L, Guan M, Zhang B et al.. “Depression in Parkinson's disease: prevalence and impact on oculomotor features.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41895089 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  46. [46]

    Shen Q, Zheng F, Dong Y et al.. “Global, regional, and national burden of Early-onset Parkinson's disease: A comprehensive analysis and forecast, 1990-2021.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41876889 ↗

    L5OTHERCited in: Epidemiology and Risk Factors, Special Populations
  47. [47]

    Jian X, Yu P, Zhang Y et al.. “Large-scale profiling of blood microbial signatures in patients with Parkinson's disease and its association with disease progression: a cross-sectional study.” EBioMedicine (2026). PMID: 41864063 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  48. [48]

    Step K, Ndong Sima CAA, Grant S et al.. “Polygenic risk scores and Parkinson's disease in South Africa advancing ancestry informed disease prediction.” PLoS genetics (2026). PMID: 41801886 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  49. [49]

    Ahn SH, Kim DH, Park J et al.. “Dynamic Smoking Patterns and Risk of Parkinson Disease and All-Cause Mortality: A Competing Risk Analysis Approach.” Neurology (2026). PMID: 41740083 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  50. [50]

    Tang X, Cui H, Cui H. “Orchestrating the Parkinson's disease microenvironment in 3D for pathogenesis study and therapeutic development.” Biofabrication (2026). PMID: 41719587 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  51. [51]

    Arias-Carrión O. “Parkinson's Disease: From Gene-Environment Risk to Precision Therapy.” Medical sciences (Basel, Switzerland) (2026). PMID: 41718119 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  52. [52]

    Onrubia-Márquez M, Garcia MM, Navas F et al.. “MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson's Behavioral Dysfunction in Mice.” International journal of nanomedicine (2026). PMID: 41710371 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  53. [53]

    Li S, Chen S, Yu X et al.. “Scoping review of AI-driven wearable technologies for rehabilitation and functional assessment in Parkinson's disease: a protocol.” BMJ open (2026). PMID: 41692525 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors
  54. [54]

    Vakhshoori M, Bondariyan N, Jones J et al.. “The impact of cardiovascular disease on Parkinson's disease: Findings from the PPMI study.” Parkinsonism & related disorders (2026). PMID: 41643580 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  55. [55]

    Li G, Li G. “The impact of diabetes mellitus in prodromal Parkinson's disease.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41639475 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  56. [56]

    Sun M, Wang X, Lu Z et al.. “GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.” Diabetes, obesity & metabolism (2026). PMID: 41582696 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  57. [57]

    Di Luca DG, de Havenon A, Prabhune A et al.. “Temporal trends and risk factors of hospital readmission following deep brain stimulation for Parkinson disease.” Parkinsonism & related disorders (2026). PMID: 41579428 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  58. [58]

    Mammen JR, Reddy V, Lerner A et al.. “Three years later: tracking bothersome symptoms and impacts for people with early Parkinson's disease.” Journal of neurology (2026). PMID: 41563488 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  59. [59]

    Park CW, Choi Y, Sun Y et al.. “Visuospatial dysfunction indicates an increased risk of rapid dementia conversion in Parkinson's disease.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2026). PMID: 41540811 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  60. [60]

    Chen W, Du M, Liu M et al.. “Co-occurrence patterns and related risk factors of dementia and Parkinson's disease among older adults across 204 countries and territories: a spatial correspondence and systematic analysis.” BMC medicine (2026). PMID: 41540403 ↗

    L5OTHERCited in: Epidemiology and Risk Factors
  61. [61]

    Wu J, Zang W, Fang M et al.. “Effects of Wearable Devices on Parkinson Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials Within the International Classification of Functioning, Disability, and Health Framework.” Journal of medical Internet research (2026). PMID: 41849761 ↗

    L1aSR_MA_RCTCited in: Diagnosis and Workup
  62. [62]

    Alla D, Shah D, Ramsundar R et al.. “Efficacy and Safety of Deferiprone for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Clinical neuropharmacology (Unknown). PMID: 41790482 ↗

    L1aSR_MA_RCTCited in: Diagnosis and Workup
  63. [63]

    Srp M, Hoskovcova M, Lagnerova R et al.. “Enhancing Adherence to Home-Based Expiratory Muscle Strength Training in Parkinson Disease: Randomized Controlled Trial of an mHealth Intervention.” Journal of medical Internet research (2026). PMID: 41812147 ↗

    L1bRCTCited in: Diagnosis and Workup, Management, Supportive Care and Complication Management
  64. [64]

    Raza H, Nizam B, Padaniya A et al.. “Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta-Analysis.” Brain and behavior (2026). PMID: 41880197 ↗

    L2aSR_OBSCited in: Diagnosis and Workup
  65. [65]

    Mohammed I, Nankya Y, Hong UT et al.. “The role of N-acetylcysteine and glutathione in the management of Parkinson's disease: a systematic review of oxidative biomarkers and clinical outcomes.” Amino acids (2026). PMID: 41874704 ↗

    L2aSR_OBSCited in: Diagnosis and Workup
  66. [66]

    Boffino CC, Holzhacker TY, Silva SMA et al.. “Effects of galvanic vestibular stimulation on motor control in patients with Parkinson's disease: study protocol.” Arquivos de neuro-psiquiatria (2026). PMID: 41759503 ↗

    L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management
  67. [67]

    Brito SAF, Scianni AA, Silveira BMF et al.. “High-intensity respiratory muscle training improves maximal respiratory pressures, breathing endurance, dyspnoea and exercise capacity in people with Parkinson's disease: a randomised trial.” Journal of physiotherapy (2026). PMID: 41933952 ↗

    L1bRCTCited in: Diagnosis and Workup, Differential Diagnosis, Management, Supportive Care and Complication Management
  68. [68]

    Coskun K, Turan GB. “The Effects of Color Therapy on Fatigue, Depression, and Quality of Life in Parkinson's Patients: A Randomized Controlled Trial.” Brain and behavior (2026). PMID: 41888497 ↗

    L1bRCTCited in: Diagnosis and Workup, Management
  69. [69]

    Baggen RJ, Van Bladel A, Prins MR et al.. “Visual perturbation training to reduce visual dependency in Parkinson's disease: A randomized controlled trial.” PloS one (2026). PMID: 41770816 ↗

    L1bRCTCited in: Diagnosis and Workup, Management
  70. [70]

    Huang H, Zhu R, Zheng Y et al.. “Effect evaluation of the positive emotion, engagement, relationships, meaning, and accomplishment (PERMA) positive psychological intervention model in patients with Parkinson's disease.” Neuropsychology (2026). PMID: 41770127 ↗

    L1bRCTCited in: Diagnosis and Workup
  71. [71]

    Lonczewski S, Bader V, Ortmann L et al.. “A Novel 3D Semi-Automated Full Quantification Technique for Detection of Intraneural Phospho-α-Synuclein in Skin Biopsies.” European journal of neurology (2026). PMID: 41995607 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations
  72. [72]

    Sowalsky KL, Okun MS, Terza M et al.. “Regular Metronome, Fractal Metronome, and Music for Parkinson Gait.” JAMA network open (2026). PMID: 41989783 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Management
  73. [73]

    Kim YJ, Choi SI, Yang H et al.. “Insole-Derived Plantar Pressure Variability Reveals Dual-Task Gait Differences in Early-Stage Parkinson's Disease.” IEEE journal of translational engineering in health and medicine (2026). PMID: 41970941 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis, Special Populations
  74. [74]

    Yu Q, Zhang Y, Huang P et al.. “Midbrain Energy Homeostasis Biomarker for Differential Diagnosis of Early-Stage Parkinson Disease: A 1H and 31P MRI Study.” Radiology (2026). PMID: 41944724 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
  75. [75]

    Zhu S, Yi W, Feng Y et al.. “Decomposed Transfer Entropy for EEG Brain Networks: Parkinson's Disease and Dopaminergic Modulation.” IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society (2026). PMID: 41941809 ↗

    L5OTHERCited in: Diagnosis and Workup, Differential Diagnosis
  76. [76]

    Akram SW, K C. “Enhancing Parkinson's Disease Staging: An Integrative Deep Learning Framework for Multimodal Feature Selection.” Journal of molecular neuroscience : MN (2026). PMID: 41910849 ↗

    L5OTHERCited in: Diagnosis and Workup
  77. [77]

    Lin J, Lee PY, Tran KKN et al.. “Detailed Outer Retinal Assessment in Parkinson's Disease Using Directional OCT.” Investigative ophthalmology & visual science (2026). PMID: 41910525 ↗

    L5OTHERCited in: Diagnosis and Workup
  78. [78]

    Noor MS, Jadapalli J, Walker HC et al.. “Localizing beta synchronous neurons in the STN using directional DBS recordings and patient-specific biophysical models.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2026). PMID: 41881902 ↗

    L5OTHERCited in: Diagnosis and Workup, Management
  79. [79]

    Boebinger SE, Payne AM, Xiao J et al.. “Cortically Mediated Muscle Responses to Balance Perturbations Increase with Perturbation Magnitude in Older Adults with and without Parkinson's Disease.” eNeuro (2026). PMID: 41871956 ↗

    L5OTHERCited in: Diagnosis and Workup
  80. [80]

    Li Z, Yang R, Cui X et al.. “Orthostatic blood pressure trajectories characterize heterogeneous disease progression in Parkinson's disease.” Journal of neurology (2026). PMID: 41870682 ↗

    L5OTHERCited in: Diagnosis and Workup
  81. [81]

    Niemi KJ, Jaakkola E, Myller EM et al.. “Striatal Dopamine Transporter and Rest Tremor in Parkinson Disease: A Clinical Validation.” Neurology (2026). PMID: 41855450 ↗

    L5OTHERCited in: Diagnosis and Workup
  82. [82]

    Wang Q, Lv M, Zhou X et al.. “Association of choroid plexus volume with MRI indices of DTI-derived parameters and perivascular spaces in patients with neurodegenerative diseases.” European journal of radiology (2026). PMID: 41849872 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Populations
  83. [83]

    Morcillo-Martínez L, Sanz-Mármol M, Romanos-Navarrete AI et al.. “Effects of a level-based immersive virtual reality physical therapy program on static and dynamic balance in Parkinson's disease: Protocol for a randomized controlled trial.” PloS one (2026). PMID: 41838745 ↗

    L2bTRIAL_NONRANDOMCited in: Diagnosis and Workup, Management, Special Populations
  84. [84]

    Wei X, Tian Y, Lu Q et al.. “Dynamic Reconfiguration of Cognitive Networks and Recovery From Microlesion Effects in Parkinson's Disease: Insights From a Longitudinal fNIRS Study.” CNS neuroscience & therapeutics (2026). PMID: 41834033 ↗

    L5OTHERCited in: Diagnosis and Workup, Management
  85. [85]

    Gravel P, Gallezot JD, Fontaine K et al.. “Variance reduction with synaptic density imaging in Parkinson's disease using direct-4D PET image reconstruction.” Physics in medicine and biology (2026). PMID: 41825140 ↗

    L5OTHERCited in: Diagnosis and Workup
  86. [86]

    Mezzini A, Kumar S, Sharrad S et al.. “The Topographical, Sensory, and Temporal Characteristics of Pain in Parkinson's Disease: A Cross-Sectional Survey.” Pain practice : the official journal of World Institute of Pain (2026). PMID: 41814463 ↗

    L5OTHERCited in: Diagnosis and Workup, Special Populations
  87. [87]

    Kassubek J, Höglinger GU, Zůza A et al.. “Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.” Journal of neurology (2026). PMID: 41811373 ↗

    L5OTHERCited in: Diagnosis and Workup
  88. [88]

    Jiang H, Chen G, Ma J et al.. “Precise estimation of tissue microstructure with hybrid graph transformer.” Artificial intelligence in medicine (2026). PMID: 41806520 ↗

    L5OTHERCited in: Diagnosis and Workup
  89. [89]

    Mîndreanu R, Chiș IC, Sevastre-Berghian A et al.. “N-Acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders.” International journal of molecular sciences (2026). PMID: 41977262 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  90. [90]

    Del Papa DF, Herman J, Kunju AT et al.. “Neurovascular Unit Dysfunction and Cerebral Small Vessel Disease in Parkinson Disease: A Systematic Review and a Meta Analysis.” Neurology (2026). PMID: 41955557 ↗

    L2aSR_OBSCited in: Differential Diagnosis, Guidelines and Resources
  91. [91]

    Hu S, Lei J, You HJ. “Exercise for Non-Motor Symptoms of Parkinson's Disease: An Evidence-Based Review of Clinical Trials, Dosing Considerations, and Mechanistic Insights.” Neural plasticity (2026). PMID: 41918452 ↗

    L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management, Supportive Care and Complication Management
  92. [92]

    de Ronde EM, Birnie E, Rijpma A et al.. “Individualised stimlation parameters in deep brain stimulation for Parkinson's disease based on disease phenotype and brain connectivity: protocol for a randomised feasibility study in a tertiary care centre (iDBS trial).” BMJ open (2026). PMID: 41974545 ↗

    L2bTRIAL_NONRANDOMCited in: Differential Diagnosis, Management
  93. [93]

    Zhu Y, Zhao L, Li Y et al.. “Disruption of Synaptic Vesicle Trafficking in Alzheimer's and Parkinson's Disease: Mechanisms and Therapeutic Implication.” International journal of molecular sciences (2026). PMID: 41977275 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  94. [94]

    Musarò D, Greco M, Lanza M et al.. “Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence.” International journal of molecular sciences (2026). PMID: 41977181 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  95. [95]

    Almeida V, Herz DM, Blech J et al.. “Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.” Translational psychiatry (2026). PMID: 41963290 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management
  96. [96]

    Ramanan S, Johnson GVW. “A Bioinformatic Analysis of BAG Protein Interactors and Pathways in Alzheimer's and Parkinson's Disease.” Journal of molecular neuroscience : MN (2026). PMID: 41925793 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  97. [97]

    Yin X, Wang C, Lin W et al.. “Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles.” International journal of nanomedicine (2026). PMID: 41907367 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis, Management
  98. [98]

    Ozkaya KS, Browning KN. “The Brain-Gut Axis in Parkinson's Disease Pathology.” Comprehensive Physiology (2026). PMID: 41905903 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  99. [99]

    Aslan FS, Barut B, Ozturk S et al.. “Neurotransmitter Dysregulation in Parkinson's Disease: Pathophysiological Insights and Therapeutic Perspectives.” ACS chemical neuroscience (2026). PMID: 41904982 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  100. [100]

    Davis A, Casmedes IY, Burton MD. “Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.” International journal of molecular sciences (2026). PMID: 41898672 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  101. [101]

    Rojas Romero CJ, Guerrero Y. “Singing-Based Interventions for Treating Hypokinetic Dysarthria in Parkinson's Disease: A Systematic Review.” Journal of music therapy (2026). PMID: 41990042 ↗

    L2aSR_OBSCited in: Differential Diagnosis, Management
  102. [102]

    Garanin AA, Aydumova OY, Rubanenko AO et al.. “[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].” Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026). PMID: 41984552 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  103. [103]

    Jin J, Jiang Y, Zhou Y et al.. “AI-Enabled Flexible Sensing Ecosystems for Parkinson's Disease: Advancing Digital Biomarkers and Closed-Loop Interventions.” Sensors (Basel, Switzerland) (2026). PMID: 41977856 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  104. [104]

    Singhal M, Grannie C, Burnette M et al.. “Freezing of Gait in Parkinson's Disease: A Scoping Review on the Path Towards Real-Time Therapies.” Sensors (Basel, Switzerland) (2026). PMID: 41977827 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  105. [105]

    Shi WQ, Zhuang JH, Zhang QH et al.. “Synthesis and Biological Evaluation of RBG Derivatives as Nrf2 Activators for the Treatment of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977502 ↗

    L5OTHERCited in: Differential Diagnosis
  106. [106]

    Toledano-Pinedo M, Porro-Pérez A, Schäker-Hübner L et al.. “Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-Based Therapy of Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41977320 ↗

    L5OTHERCited in: Differential Diagnosis
  107. [107]

    Yang JC, Situ J, Troutman R et al.. “A microbiome quantitative trait locus in SLC39A8 modulates disease severity in synucleinopathy-induced models of Parkinson's disease.” Human molecular genetics (2026). PMID: 41955304 ↗

    L5OTHERCited in: Differential Diagnosis
  108. [108]

    Yang D, Xu J, Zhu Y et al.. “The genetic associations of DNAJC family members with Parkinson's disease: comprehensive evidence from burden analysis and Mendelian randomization.” Human genetics (2026). PMID: 41951985 ↗

    L5OTHERCited in: Differential Diagnosis
  109. [109]

    Gowied HG, El-Mezayen NS, Afify EA. “Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.” Life sciences (2026). PMID: 41936814 ↗

    L5OTHERCited in: Differential Diagnosis
  110. [110]

    Ahumada-Montalva P, Muñoz-Carvajal F, Bórquez-Macaya S et al.. “TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson's disease.” Cell death & disease (2026). PMID: 41932887 ↗

    L5OTHERCited in: Differential Diagnosis
  111. [111]

    Liu C, Jin Y, Lin H et al.. “Effects of transcutaneous auricular vagus nerve stimulation on motor and gait performance in Parkinson's disease: a meta-analysis of randomized controlled trials.” Journal of neurology (2026). PMID: 41805933 ↗

    L1aSR_MA_RCTCited in: Management, Supportive Care and Complication Management
  112. [112]

    Jun JS, Kang N, Park K et al.. “Cycling exercise for autonomic symptoms in early Parkinson's disease.” Autonomic neuroscience : basic & clinical (2026). PMID: 41740291 ↗

    L1bRCTCited in: Management, Supportive Care and Complication Management
  113. [113]

    Fidan C. “Technologies used in Parkinson's disease: a meta-analysis of their effect on health-related quality of life.” Journal of neurology (2026). PMID: 41817821 ↗

    L2aSR_OBSCited in: Management
  114. [114]

    Zhang X, Zheng L, Li Y et al.. “Efficacy of rTMS and TBS on the motor symptoms in Parkinson's disease: a network meta-analysis.” Journal of neurology (2026). PMID: 41817817 ↗

    L2aSR_OBSCited in: Management
  115. [115]

    Senthilkumar S, S M, Rizvi MF et al.. “Deep brain stimulation beyond Motor control: A systematic review and meta-analysis of sleep outcomes in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41702753 ↗

    L2aSR_OBSCited in: Management
  116. [116]

    van der Linden C, Berger T, Dembek TA et al.. “Tractography-guided versus clinical contact selection for deep brain stimulation in tremor - A prospective clinical trial.” Brain stimulation (2026). PMID: 41740836 ↗

    L2bTRIAL_NONRANDOMCited in: Management
  117. [117]

    Zhang R, Feng R, Wang J et al.. “Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial.” Signal transduction and targeted therapy (2026). PMID: 41826284 ↗

    L1bRCTCited in: Management
  118. [118]

    Ferrara PE, Della Casa E, Calciano R et al.. “Effects of Focal Muscle Vibration on Static and Dynamic Balance in Patients with Parkinson's Disease: Preliminary Results of a Retrospective Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752699 ↗

    L2bCOHORTCited in: Management
  119. [119]

    Hu W, Li Y, Yang A et al.. “Research progress on employing medicinal plants and their active compounds to target autophagic pathways for Parkinson's disease therapy.” Journal of ethnopharmacology (2026). PMID: 41895540 ↗

    L2aSR_OBSCited in: Management
  120. [120]

    Pinheiro RSA, Silva Júnior HBD, Guimarães BB et al.. “Effects of Transcranial Direct Current Stimulation on Speech and Voice Changes in Parkinson's Disease: a Systematic Review with Meta-Analysis.” CoDAS (2026). PMID: 41779498 ↗

    L2aSR_OBSCited in: Management
  121. [121]

    Busot D, Yang H, Sawmiller D et al.. “The Progress of Active Immunotherapy for Parkinson's Disease.” International journal of molecular sciences (2026). PMID: 41828418 ↗

    L5REVIEW_NARRATIVECited in: Management
  122. [122]

    Jost ST, Atwani C, Loehrer PA et al.. “Patients with symmetric Parkinson's disease do poorly with subthalamic stimulation.” Journal of neurology, neurosurgery, and psychiatry (2026). PMID: 41781214 ↗

    L5OTHERCited in: Management
  123. [123]

    Li J, Liu T, Wei J. “Exercise as Chronotherapy: Regulating Circadian Rhythms to Alleviate Symptoms in Parkinson's Disease.” ACS chemical neuroscience (2026). PMID: 41766127 ↗

    L5REVIEW_NARRATIVECited in: Management
  124. [124]

    Rajyasree A, Balamurugan J. “"Every day is a battle against Parkinson's"-a qualitative study on older adults at the long-term care facilities in Chennai.” Frontiers in public health (2026). PMID: 41756082 ↗

    L5OTHERCited in: Management, Special Populations
  125. [125]

    Qiu S, Wei Y, Gao C et al.. “Effects of combined transcranial direct current stimulation and gait training in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.” Systematic reviews (2025). PMID: 41053827 ↗

    L1aSR_MA_RCTCited in: Supportive Care and Complication Management
  126. [126]

    Lima JL, Inacio PA, Sá Filho A et al.. “Effectiveness of virtual reality rehabilitation with exergames on functional rehabilitation in Parkinson's disease: a systematic review of chronic randomized controlled trials.” Expert review of neurotherapeutics (2025). PMID: 40963232 ↗

    L1aSR_MA_RCTCited in: Supportive Care and Complication Management
  127. [127]

    Madrid J, Batzianouli E, Rutz D et al.. “Can transcranial Direct Current Stimulation enhance the efficacy of a rehabilitative intervention for the treatment of Freezing of Gait in Parkinson's disease? A double-blind, randomized controlled study.” Journal of Parkinson's disease (2026). PMID: 41637203 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  128. [128]

    Matsushita W, Nagaki K, Takashi N et al.. “Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41637155 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  129. [129]

    Villamil-Cabello E, Molinero-Martín E, Luque-Casado A et al.. “Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial.” Journal of Parkinson's disease (2026). PMID: 41615860 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  130. [130]

    Eldemir S, Polat EA, Gokdogan CM et al.. “The effect of rebound therapy in Parkinson's disease: A single-blinded randomized controlled trial.” Gait & posture (2026). PMID: 41592453 ↗

    L1bRCTCited in: Supportive Care and Complication Management, Special Populations
  131. [131]

    Wang R, Liu M, Liu Q et al.. “Home-based transcutaneous auricular vagus nerve stimulation (taVNS) improves motor and non-motor symptoms by improving autonomic and brain functions in patients with Parkinson's disease: A randomized clinical trial.” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics (2026). PMID: 41549029 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  132. [132]

    Kalva-Filho CA, Zampier VC, Orcioli-Silva D et al.. “Inter-effort recovery hypoxia did not mitigate acute treadmill effects in people with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41389475 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  133. [133]

    Rascol O, Ory-Magne F, Meissner WG et al.. “Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41316871 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  134. [134]

    da Conceição NR, Vitório R, Morya E et al.. “Effect of Dynamic Balance Training Combined with Different Intensities of Cerebellar Transcranial Direct Current Stimulation in People with Parkinson's Disease: a Randomized Clinical Trial.” Cerebellum (London, England) (2025). PMID: 41239034 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  135. [135]

    Topal A, Durmaz Çelik N, Ayık B et al.. “Effect of a Wearable Sensor-Based Posture Correction Brace on Static Balance and Posture in Parkinson's Disease.” American journal of physical medicine & rehabilitation (2026). PMID: 41082253 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  136. [136]

    Thanakamchokchai J, Ajjimaporn A, Richards J et al.. “High-frequency rTMS and home-based exercise in individuals with Parkinson's disease: A double-blind randomized controlled trial.” Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2025). PMID: 40934835 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  137. [137]

    Hernandez-Martinez J, Branco BHM, Cid-Calfucura I et al.. “Exergaming Compared to Conventional Physical Exercise Interventions on Health Status in Older People with Parkinson's Disease: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.” Medicina (Kaunas, Lithuania) (2025). PMID: 41303837 ↗

    L1aSR_MA_RCTCited in: Supportive Care and Complication Management
  138. [138]

    Mollinedo-Cardalda I, Monge-Pereira E, Pereira-Pedro KP et al.. “Acute effects of an aerobic dual task on processing speed and attention in Parkinson's disease: a randomised controlled trial study.” Journal of bodywork and movement therapies (2025). PMID: 41316559 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  139. [139]

    Li Y, Liu Y, Lin Z et al.. “Aerobic exercise modulates plasma oxidized lipid metabolites and neurotransmitters in Parkinson's disease motor subtypes.” Brain research (2025). PMID: 41205731 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  140. [140]

    Zeng B, Wang H, Chen J et al.. “Optimal exercise modalities and doses for improving quality of life in patients with Parkinson's disease: a network meta-analysis and dose-response study.” Journal of neurology (2026). PMID: 41656425 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  141. [141]

    Yan HL, Li MM. “Effects of exercise modalities on cognitive function and depression in patients with Parkinson's disease: A systematic review and network meta-analysis.” Geriatric nursing (New York, N.Y.) (2025). PMID: 41129905 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  142. [142]

    Han C, Zhang H, Wang Q et al.. “Physical exercise and inflammation in Parkinson's disease: a review.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 41085917 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  143. [143]

    Decaix T, Bonnin C, Götze K et al.. “Benefits of physical activity on cognitive function in patients with neurocognitive disorders: A systematic review.” The Journal of frailty & aging (2025). PMID: 40911419 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  144. [144]

    Xiao C, Zhou F. “Yi Jin Jing Exercise Program Improves in Cognition, Sleep and Functional Mobility for Mild and Moderate Parkinson 's Disease: A Randomized Controlled Trial.” Experimental aging research (2026). PMID: 41388828 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  145. [145]

    Fukuchi CA, Moreno VC, Kalva-Filho CA et al.. “Combining automated mechanical peripheral stimulation and treadmill exercise for gait rehabilitation in Parkinson's disease: A randomized controlled trial.” Clinical biomechanics (Bristol, Avon) (2026). PMID: 41337903 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  146. [146]

    González-García P, Heredia-Rizo AM, Garrido-Bueno A et al.. “Multi-Session whole body vibration program on Parkinson's disease symptoms: Systematic review and meta-analysis.” Journal of bodywork and movement therapies (2025). PMID: 41316661 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  147. [147]

    Domínguez-Pera I, Lucena-Anton D, Estebanez-Perez MJ et al.. “Efficacy of transcranial direct current stimulation combined with gait training in patients with Parkinson's disease: Systematic review and meta-analysis.” CNS spectrums (2025). PMID: 41065007 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  148. [148]

    Taveira RS, Vasconcellos LS, Bezerra CF et al.. “Telerehabilitation for people with Parkinson's disease: protocol of a randomised clinical trial of mixed methods.” BMJ open (2025). PMID: 41320221 ↗

    L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
  149. [149]

    Tufft A, Neilens H, Marsden J et al.. “Efficacy of peroneal nerve functional electrical stimulation (FES) for the reduction of bradykinesia in Parkinson's disease: an assessor-blinded randomised controlled trial (STEPS II)-study protocol.” BMJ open (2025). PMID: 40912703 ↗

    L2bTRIAL_NONRANDOMCited in: Supportive Care and Complication Management
  150. [150]

    Greenland JC, Dresser K, Cutting E et al.. “Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.” The Lancet. Neurology (2026). PMID: 41389828 ↗

    L1bRCTCited in: Special Populations
  151. [151]

    Song T, Xiang L, Liu Y et al.. “Survival and related factors in patients with Parkinson's disease: a multicenter prospective cohort study in China.” Journal of neurology (2026). PMID: 41507598 ↗

    L2bCOHORTCited in: Special Populations
  152. [152]

    Fleet JL, Carter B, Cadarette SM et al.. “Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026). PMID: 41369770 ↗

    L2bCOHORTCited in: Special Populations
  153. [153]

    Erfmann K, Hirschwald J, Hofacker J et al.. “Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.” Movement disorders : official journal of the Movement Disorder Society (2026). PMID: 41508417 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  154. [154]

    Hickman J, Tsai A, Fullard M et al.. “Early-Onset Parkinson's Disease: Unique Features and Management Approaches.” Current neurology and neuroscience reports (2025). PMID: 41410819 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  155. [155]

    Calzada García M, Ayala A, Navarta Sánchez MV et al.. “[Impact of a community-based multisectoral intervention on the health of individuals with parkinson's disease and their family caregivers].” Semergen (2026). PMID: 41707402 ↗

    L1bRCTCited in: Special Populations
  156. [156]

    Machane D, Shaji MS, Borchman D et al.. “Meibum Lipid Saturation Related to Dry Eye, Age, and Sex Using Nuclear Magnetic Resonance Spectroscopy.” Investigative ophthalmology & visual science (2026). PMID: 41910524 ↗

    L5OTHERCited in: Special Populations
  157. [157]

    Sriram D, Pourzinal D, Bailey DX et al.. “Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 41834361 ↗

    L5OTHERCited in: Special Populations, Guidelines and Resources
  158. [158]

    Hatakeyama S, Miki Y, Tanaka MT et al.. “Cerebrospinal fluid HOMER1 and NPTX2 as candidate signatures in early-stage multiple system atrophy-parkinsonism.” Journal of the neurological sciences (2026). PMID: 41780424 ↗

    L5OTHERCited in: Special Populations
  159. [159]

    Lian J, Fan Z, Petrazzini BO et al.. “Subtyping Alzheimer's disease and Parkinson's disease using longitudinal electronic health records.” Nature aging (2026). PMID: 41748957 ↗

    L5OTHERCited in: Special Populations
  160. [160]

    Falk L, Brunius C, Crnic Bojkovic T et al.. “A data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.” NeuroImage. Clinical (2026). PMID: 41719754 ↗

    L5OTHERCited in: Special Populations
  161. [161]

    Bolsewig K, Bellomo G, Hok-A-Hin YS et al.. “A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.” Nature medicine (2026). PMID: 41699128 ↗

    L5OTHERCited in: Special Populations
  162. [162]

    Anis S, Kundrick A, Callegari Piccinin C et al.. “Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary center.” Parkinsonism & related disorders (2026). PMID: 41691977 ↗

    L5OTHERCited in: Special Populations
  163. [163]

    Ou C, Chen B, Yu H et al.. “Association between the triglyceride-glucose frailty index and Parkinson's disease in middle-aged and older adults: a comparative cross-national analysis of NHANES and CHARLS.” Parkinsonism & related disorders (2026). PMID: 41691976 ↗

    L5OTHERCited in: Special Populations
  164. [164]

    Kim D, Tjaden K, Stipancic KL et al.. “Variable Speech Cueing Effects in Talkers With Parkinson's Disease.” American journal of speech-language pathology (2026). PMID: 41666082 ↗

    L5OTHERCited in: Special Populations
  165. [165]

    Gunawardana CW, Burke PGR, Ignatavicius A et al.. “Comparing phenotypic features between Parkinson's disease dementia and dementia with Lewy bodies.” Journal of neurology (2026). PMID: 41665721 ↗

    L5OTHERCited in: Special Populations
  166. [166]

    Singovski S, Harlé L, Zerbit J et al.. “Continuous subcutaneous apomorphine infusion to improve comfort in advanced degenerative Parkinsonian syndrome patients: a retrospective descriptive study in a home-based setting.” Parkinsonism & related disorders (2026). PMID: 41653908 ↗

    L5OTHERCited in: Special Populations
  167. [167]

    Hobson R, Levy SHS, Singal CMS et al.. “Clonal CD8+ T cells populate the leptomeninges and coordinate with immune cells in human degenerative brain diseases.” Nature immunology (2026). PMID: 41593242 ↗

    L5OTHERCited in: Special Populations
  168. [168]

    Pourzinal D, Brooks D, Sriram D et al.. “Best practice guidelines for the diagnosis, evaluation, and management of cognitive disorders in Parkinson's disease.” Age and ageing (2026). PMID: 41870152 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  169. [169]

    Fanciulli A, Sixel-Döring F, Buhmann C et al.. “Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2025). PMID: 39751950 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  170. [170]

    Vieira SRL, Mezabrovschi R, Toffoli M et al.. “Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.” Movement disorders : official journal of the Movement Disorder Society (2024). PMID: 39258449 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  171. [171]

    Witt K, Levin J, van Eimeren T et al.. “Diagnostics and treatment of impulse control disorders, psychosis and delirium: systemic review-based recommendations - guideline "Parkinson's disease" of the German Society of Neurology.” Journal of neurology (2024). PMID: 39046524 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  172. [172]

    Tönges L, Buhmann C, Eggers C et al.. “Guideline "Parkinson's disease" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie): concepts of care.” Journal of neurology (2024). PMID: 38969876 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  173. [173]

    Walter U, Loewenbrück KF, Dodel R et al.. “Systematic review-based guideline "Parkinson's disease" of the German Society of Neurology: diagnostic use of transcranial sonography.” Journal of neurology (2024). PMID: 38963440 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  174. [174]

    Ó Breasail M, Singh KP, Lithander FE et al.. “Management of Osteoporosis in Parkinson's Disease: A Systematic Review of Clinical Practice Guidelines.” Movement disorders clinical practice (2025). PMID: 39704021 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  175. [175]

    Maia DP, Cury RG, Brandão PRP et al.. “Guidelines for Parkinson's disease management part II: consensus from the movement disorders scientific department of the Brazilian Academy of Neurology - non-motor symptoms.” Arquivos de neuro-psiquiatria (2025). PMID: 39993447 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  176. [176]

    Liao J, Wang L, Liu R et al.. “Altered regional spontaneous brain activity in Parkinson's disease: a meta-analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41579202 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  177. [177]

    Li S, Yang C, Wu J et al.. “Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis.” Journal of neurology (2025). PMID: 41324773 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  178. [178]

    Garon M, Weck C, Leta V et al.. “Early thinking palliative care for people with Parkinson's disease: A thematic synthesis based on a systematic mixed-methods review.” Journal of Parkinson's disease (2025). PMID: 40320755 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  179. [179]

    Guidetti M, Marceglia S, Bocci T et al.. “Is physical therapy recommended for people with parkinson's disease treated with subthalamic deep brain stimulation? a delphi consensus study.” Journal of neuroengineering and rehabilitation (2025). PMID: 40211348 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  180. [180]

    Rosado-Martins F, Santos B, Costa CM et al.. “Vestibular Dysfunction in Parkinson's Disease: A Systematic Review of Signs and Symptoms.” Movement disorders clinical practice (2026). PMID: 40854008 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  181. [181]

    Veilleux Carpentier A, Malaty IA, LeWitt PA et al.. “A Systematic Review of the Parkinson's Foundation Hospital Care Recommendations.” Movement disorders clinical practice (2026). PMID: 40736219 ↗

    L2aSR_OBSCited in: Guidelines and Resources
  182. [182]

    Lima DP, Gomes VC, Luna JRG et al.. “Assessment of sarcopenia tools as predictors of falls in patients with mild to moderate Parkinson's Disease: A cohort study.” Clinics (Sao Paulo, Brazil) (2025). PMID: 40972508 ↗

    L2bCOHORTCited in: Guidelines and Resources
  183. [183]

    Cordillet S, Drapier S, Leh F et al.. “Detecting Freezing of Gait in Parkinson Disease Using Multiple Wearable Sensors Sets During Various Walking Tasks Relative to Medication Conditions (DetectFoG): Protocol for a Prospective Cohort Study.” JMIR research protocols (2025). PMID: 39913915 ↗

    L2bTRIAL_NONRANDOMCited in: Guidelines and Resources
  184. [184]

    Gülke E, Lewis SJG. “What is new in Freezing of Gait?” Journal of neurology (2026). PMID: 41865085 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  185. [185]

    Chen K, Hao W, Ji Y et al.. “Two novel iron metabolism-related genes identified as diagnostic indicators in substantia nigra of patients with Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41643581 ↗

    L5OTHERCited in: Guidelines and Resources
  186. [186]

    Anis S, Clark PA, Shaffer S et al.. “Introducing a workflow algorithm for adaptive DBS programming in Parkinson's disease.” Parkinsonism & related disorders (2026). PMID: 41577516 ↗

    L5OTHERCited in: Guidelines and Resources
  187. [187]

    Safarpour D, Brooks A, Smiley A et al.. “Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41490026 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  188. [188]

    Pedrosa AJ, Molter JN, Brito de Almeida L et al.. “A modified Delphi study of post-operative management for subthalamic deep brain stimulation in Parkinson's disease.” Journal of Parkinson's disease (2026). PMID: 41217788 ↗

    L5OTHERCited in: Guidelines and Resources
  189. [189]

    Rosenbohm A, Nguyen-Younossi N, Kassubek J. “Parkinson's disease-associated camptocormia: biopsy-confirmed focal myositis and treatment options.” Journal of neurology (2025). PMID: 41131373 ↗

    L5OTHERCited in: Guidelines and Resources
  190. [190]

    Houston E, Boyd S, Iyer V et al.. “The need for developing consensus-based guidelines in assessing Parkinson's disease laterality.” Parkinsonism & related disorders (2025). PMID: 41039696 ↗

    L5OTHERCited in: Guidelines and Resources
  191. [191]

    Poplawska-Domaszewicz K, Kaasinen V, van der Plas AA et al.. “Management of neuropsychiatric, motor and non-motor symptoms in Parkinson´s disease after long distance air travel: a consensus view.” Journal of neural transmission (Vienna, Austria : 1996) (2025). PMID: 40986033 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  192. [192]

    Sajin V, Goodall M, Macerollo A. “Camptocormia in Parkinson's disease: state of the art and future directions.” Journal of neurology (2025). PMID: 40975851 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources
  193. [193]

    Wang S, Zhou F, Fang X et al.. “Evidence-based summary of the prevention and management of constipation in patients with Parkinson's disease.” Geriatric nursing (New York, N.Y.) (2025). PMID: 40834448 ↗

    L5OTHERCited in: Guidelines and Resources
  194. [194]

    Middlebrooks EH, Bot M, Patriat R et al.. “Multi-institutional recommendations on the use of 7T MRI in deep brain stimulation.” Journal of neurosurgery (2025). PMID: 40614283 ↗

    L5REVIEW_NARRATIVECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…